Cagri-Sema Blend

The Cagri-Sema Blend combines cagrilintide, a long-acting amylin receptor agonist, with semaglutide, a GLP-1 receptor agonist, in a single research formulation. This combination mirrors the CagriSema program under clinical investigation by Novo Nordisk, which explores the complementary pharmacology of simultaneous amylin and GLP-1 receptor activation. Cagrilintide activates AMY1R and AMY3R receptors in brain regions involved in appetite regulation, while semaglutide activates GLP-1 receptors in overlapping but distinct neuronal populations. The rationale for combining these two peptides is based on their non-redundant mechanisms — amylin and GLP-1 act through separate receptor systems that converge on satiety and metabolic signaling pathways. Published clinical data suggest the combination produces effects beyond what either agent achieves individually, consistent with mechanistic complementarity.

The Cagri-Sema Blend has been investigated for its dual engagement of amylin and GLP-1 receptor systems. Cagrilintide activates amylin receptors (CTR/RAMP heterodimers) in the area postrema and hindbrain, modulating gastric emptying and central satiety signaling. Semaglutide activates GLP-1R in the hypothalamus, area postrema, and peripheral tissues including pancreatic beta cells, where it potentiates glucose-dependent insulin secretion. Researchers observed that these two receptor systems engage partially overlapping neuronal circuits but through distinct intracellular signaling cascades. Studies suggest that amylin receptor activation primarily modulates meal size and gastric motility, while GLP-1R activation influences both meal size and meal frequency through distinct CNS mechanisms. In clinical studies, the combination was associated with additive or synergistic effects on metabolic parameters compared to either component alone, supporting the concept of complementary receptor pharmacology.

CagriSema Phase 1b

Enebo et al. (2021) investigated the co-administration of cagrilintide and semaglutide in a Phase 1b trial. Researchers observed that the combination was associated with greater changes in body weight than semaglutide 2.4mg alone, with an acceptable tolerability profile [1].

Amylin-GLP-1 Complementarity

Liberini et al. (2016) investigated the neuronal basis for amylin and GLP-1 receptor interactions in the area postrema. Researchers observed that amylin and GLP-1 activate distinct but overlapping neuronal populations, providing the mechanistic basis for combination approaches [2].

CagriSema Phase 2 Data

Frias et al. (2023) reported results from a Phase 2 trial of cagrilintide 2.4mg plus semaglutide 2.4mg in subjects with type 2 diabetes. The combination was associated with changes in HbA1c and body weight beyond those observed with semaglutide alone [3].